These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26932414)

  • 1. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
    Zeng QL; Li CX; Zhang DW; Li W; Xu GH; Yu ZJ
    Aliment Pharmacol Ther; 2016 Apr; 43(7):842-3. PubMed ID: 26932414
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.
    Lai CL; Wong VW; Yuen MF; Yang JC; Knox SJ; Mo H; Han LL; Brainard DM; Chan HL
    Aliment Pharmacol Ther; 2016 Jan; 43(1):96-101. PubMed ID: 26503414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients.
    Ullah A; Maryam A; Malik G; Hameed H; Hussain K; Ahmad J; Haq I; Haq M; M Aljowaie R; Mohsen Abougazia E; Chen TW; Ahmad J; Bashir K; Ahmad L; Ahmad B
    Pak J Pharm Sci; 2023 May; 36(3(Special)):1009-1015. PubMed ID: 37587711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
    Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
    Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
    Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
    [No Abstract]   [Full Text] [Related]  

  • 9. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
    Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
    Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
    Yoshikawa A; Terashita K; Morikawa K; Matsuda S; Yamamura T; Sarashina K; Nakano S; Kobayashi Y; Sogabe S; Takahashi K; Haba S; Oda H; Takahashi T; Miyagishima T; Sakamoto N
    Clin J Gastroenterol; 2017 Jun; 10(3):270-273. PubMed ID: 28447325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of sofosbuvir in treating hepatitis C infection?
    Carey L
    JAAPA; 2015 Feb; 28(2):16-9. PubMed ID: 25621961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: self-pay behaviour patients with chronic hepatitis C who required direct acting anti-viral urgently in a real-world setting.
    Chen TM; Li YC; Huang PT
    Aliment Pharmacol Ther; 2016 Mar; 43(6):752. PubMed ID: 26876292
    [No Abstract]   [Full Text] [Related]  

  • 16. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Flisiak R; Łucejko M; Mazur W; Janczewska E; Berak H; Tomasiewicz K; Mozer-Lisewska I; Kozielewicz D; Gietka A; Sikorska K; Wawrzynowicz-Syczewska M; Nowak K; Zarębska-Michaluk D; Musialik J; Simon K; Garlicki A; Pleśniak R; Baka-Ćwierz B; Olszok I; Augustyniak K; Stolarz W; Białkowska J; Badurek A; Piekarska A
    Adv Med Sci; 2017 Sep; 62(2):387-392. PubMed ID: 28554119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness Of Sofosbuvir And Ribavirin In Hepatitis C Genotype 3 Relapsers.
    Jawaid AH; Muhammad N; Khan HM; Ali OM; Shah MA; Saad M; Jawaid FH
    J Ayub Med Coll Abbottabad; 2021; 33(1):49-53. PubMed ID: 33774954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.